Jennifer Sheldon, NP
Adult Health · Macon, GANPI 1548692700
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 44.4% of the total. Reporting peaked in 2021 at $8,531 and has fallen 73.7% since, to $2,242 in 2025. Among adult health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 567 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$8K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Amgen$602
- Xeris Pharmaceuticals, Inc.$570
- Novartis$546
- plus $5K from 38 others
What the payments were for
- Speaking & faculty fees$6,84340%
- Travel & lodging$941%
- Food & beverage$10,17559%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$4,760
- TOUJEO$2,083
- GVOKE PFS$233
- Ozempic$125
- TEPEZZA$122
- MINIMED 780G$121
How this compares
$17,124 in reported general payments places this provider in the 95th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 547 | $916,593 |
| MounjaroTirzepatide | 285 | $437,403 |
| JardianceEmpagliflozin | 326 | $347,534 |
| TrulicityDulaglutide | 146 | $203,480 |
| Tresiba Flextouch U-200Insulin Degludec | 94 | $145,348 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 35 | $101,624 |
| Tresiba Flextouch U-100Insulin Degludec | 145 | $97,955 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 63 | $61,249 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $60,982 |
| RybelsusSemaglutide | 35 | $53,516 |
| Humalog Kwikpen U-100Insulin Lispro | 133 | $52,569 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $48,148 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $41,500 |
| Novolog FlexpenInsulin Aspart | 100 | $38,681 |
| Humulin R U-500Insulin Regular, Human | 13 | $37,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,559 | $1,023,054660 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Humalog Mix 75-25 | $1,257 | $688,045573 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $147 | $378,661362 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $7,605 | $46,10144 claims |
| AstraZenecaFarxiga | $341 | $28,50322 claims |
| Johnson & JohnsonInvokana | $16 | $21,20216 claims |
| AbbVieSynthroid | $193 | $11,803145 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $267 | $4,431472 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 577 adult health providers in Georgia.
Other adult health in Macon
- Stephanie WilliamsMacon$8K
- Kayla JonesMacon$8K
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.